Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 62.00
Bid: 61.00
Ask: 63.00
Change: 0.50 (0.81%)
Spread: 2.00 (3.279%)
Open: 61.50
High: 62.00
Low: 61.50
Prev. Close: 61.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

16 Oct 2008 07:00

RNS Number : 9607F
Oxeco PLC
16 October 2008
 



16 October 2008

Oxeco Plc (the "Company" or the "Group" )

Interim financial report for the six months ended 31 July 2008

Chairman's Statement

I am pleased to report on your Group's performance for the six months ended 31 July 2008. 

Oxeco Plc is a holding and management company, specialising in the development and growth of trading businesses within the technology and science sectors. The Company currently has one subsidiary, Oxray Ltd, which was acquired in June 2007 and is a start up business which aims to become a leading provider of molecular structure determination services to both industry and academic institutions. 

The unaudited consolidated loss before tax for the Group in six months to 31 July 2008 amounted to £105,000 compared to £3,000 for the comparable period from incorporation on 17 October 2006 to 31 July 2007. Consolidated net assets at 31 July 2008 amounted to £4.77 million including cash balances of £2.64 million versus net assets of £4.93 million and cash balances of £2.81 million a year earlier at 31 July 2007. The cash outflow for the Group during the six months to 31 July 2008 amounted to £120,000 and cash balances continue to be managed prudently, with tight cost control.

Oxray's primary objectives are the development of novel X-ray crystallography structure determination software and the provision of a small-molecule X-ray crystallography structure service. The service uses a web portal behind which the company can work to maximise the extent to which the service can be automated. The Company offers standardised response times to its customers but also offers market premium services such as a fast-response and extended scientific reporting suitable to support customers' patent applications. Oxray expects to complete the initial development of it's X-ray crystallography structure determination software within the next six months and will then focus on the marketing of the service and the establishment of a solid customer base.

Oxeco Plc is well capitalised and I am confident that your Company will continue to make considerable progress in its development during the second half of the year despite turbulent financial marketsYour Directors are continuing to evaluate a range of new commercial and acquisition opportunities which they believe fulfil the Company's original objectives of investing in the technology and science sectors, and especially those which are complimentary to the existing Group activities.

Finally I would like to conclude by thanking our employees and management for their hard work and support in the growth and development of the Group in the period.

Jussi Westergren

Executive Chairman

Contact:

Michael Bretherton

Oxeco plc

www.oxecoplc.com

+44 (0) 207352 8989

 Ray Zimmerman/Jonathan Evans

Zimmerman Adams International Limited

+44 (0) 207 060 1760

Daniel Briggs

Religare Hichens, Harrison plc

+44 (0) 207 382 7776

 

 

 

 

OXECO PLC

CONDENSED CONSOLIDATED INCOME STATEMENT

FOR THE SIX MONTHS TO 31 JULY 2008

 
Notes
Six months to 31 July
2008
(Unaudited)
Period to
31 July
2007
(Unaudited)
Period to
31 January
2008
(Audited)
 
 
£000
£000
£000
 
 
 
 
 
Revenue
 
6
-
7
Administrative expenses
 
(188)
(95)
(243)
 
 
 
 
 
Operating Loss
 
(182)
(95)
(236)
 
 
 
 
 
Interest receivable
 
77
92
178
 
 
 
 
 
Loss before tax
 
(105)
(3)
(58)
 
 
 
 
 
Taxation
2
3
(5)
 
 
 
 
 
Loss for the period
 
(102)
(3)
(63)
Earnings per share Basic and Diluted
3
(0.02p)
(0.00)p
(0.01)p
 
 

 

Comparative figures comprise the period from incorporation on 17 October 2006 to 31 July 2007 and from the period from incorporation on 17 October 2006 to 31 January 2008.

The loss for the period arises from the Group's continuing operations.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS TO 31 JULY 2008

 
Share Capital £000
Share Premium £000
Retained Loss £000
Total Equity £000
At 17 October 2006
Issue of shares
600
4,500
5,100
Expenses of issue of shares
(167)
(167)
Loss for the period
(3)
(3)
At 31 July 2007
600
4,333
(3)
4,930
Loss for the period
-
-
(60)
(60)
At 31 January 2008
600
4,333
(63)
4,870
Loss for the period
-
-
(102)
(102)
At 31 July 2008
600
4,333
(165)
4,768
 
 

OXECO PLC

CONDENSED CONSOLIDATED BALANCE SHEET

AS AT 31 JULY 2008

 
Notes
31 July 2008
31 July 2007
31 January 2008
 
 
(Unaudited)
(Unaudited)
(Audited)
 
 
£000
£000
£000
ASSETS
Non-current assets
 
 
 
 
Property, plant and equipment
 
1
1
2
Intangible assets - goodwill
 
2,120
2,120
2,120
Total non-current assets
 
2,121
2,121
2,122
 
 
 
 
 
Current assets
 
 
 
 
Trade and other receivables
 
38
16
29
Cash and cash equivalents
 
2,641
2,816
2,761
Total current assets
 
2,679
2,832
2,790
 
 
 
 
 
TOTAL ASSETS
 
4,800
4,953
4,912
 
 
 
 
 
LIABILITIES
 
 
 
 
Current Liabilities
 
 
 
 
Trade and other payables
 
(30)
(23)
(37)
Current taxation
 
(2)
-
(5)
 
 
 
 
 
TOTAL LIABILITIES
 
(32)
(23)
(42)
 
 
 
 
 
NET ASSETS
 
4,768
4,930
4,870
 
 
 
 
 
EQUITY
 
 
 
 
Issued capital
3
600
600
600
Share premium
 
4,333
4,333
4,333
Revenue reserve
 
(165)
(3)
(63)
TOTAL EQUITY SHAREHOLDERS’ FUNDS
 
4,768
4,930
4,870
 
 

 

Approved by the Board and authorised for issue on 16 October 2008.

J P Westergren M A Bretherton

Chairman Finance Director

OXECO PLC

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

FOR THE SIX MONTHS ENDED 31 JULY 2008

 
Six months to
31 July 2008
Period to
31 July 2007
Period to
31 January 2008
 
(Unaudited)
(Unaudited)
(Audited)
 
£000
£000
£000
OPERATING ACTIVITIES
 
 
 
Operating loss before taxation
(182)
(95)
(236)
Depreciation of property, plant and equipment
1
-
-
Increase in trade and other receivables
(9)
(16)
(29)
Decrease in trade and other payables
(7)
(30)
(15)
Net cash outflow from operations
(197)
(141)
(280)
 
 
 
 
INVESTING ACTIVITIES
 
 
 
Purchase of property, plant and equipment
-
-
(2)
Acquisition of subsidiaries
-
(100)
(100)
Cash and bank in subsidiaries at acquisition
-
32
32
Net cash outflow from investing activities
-
(68)
(70)
 
 
 
 
FINANCING ACTIVITIES
 
 
 
Proceeds from issue of share capital
-
3,100
3,100
Expenses of issue of share capital
-
(167)
(167)
Interest received
77
92
178
Net cash inflow from financing activities
77
3,025
3,111
 
 
 
 
(DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS
(120)
2,816
2,761
 
 
 
 
Cash and cash equivalents at start of period
2,761
-
 
 
 
 
CASH AND CASH EQUIVALENTS AT END OF PERIOD
2,641
2,816
2,761
 
 

Comparative figures comprise the period from incorporation on 17 October 2006 to 31 July 2007 and from the period from incorporation on 17 October 2006 to 31 January 2008.

OXECO PLC

NOTES TO THE CONDENSED FINANCIAL STATEMENTS 

FOR THE SIX MONTHS ENDED 31 JULY 2008

1) SIGNIFICANT ACCOUNTING POLICIES

Basis of preparation

The interim financial statements of Oxeco Plc are unaudited condensed consolidated financial statements for the period for the six months period to 31 July 2008. These include unaudited comparatives for the period from incorporation on 1October 2006 to 31 July 2007 together with audited comparatives for the period from incorporation on 17 October 2006 to 31 July 2007.

The condensed consolidated financial statements have been prepared under the historic cost convention and incorporate the financials of Oxeco Plc for the period and its subsidiary undertaking from the date of acquisition.

The accounting policies adopted are consistent with those followed in the preparation of the Group's annual financial statements for the period ended 31 January 2008.

The condensed consolidated financial statements do not constitute statutory accounts. The statutory accounts for the period to 31 January 2008 have been reported on by the Company's auditors and have been filed with the Registrar of Companies. The report of the auditors was unqualified and did not contain a statement under section 237(2) or 237(3) of the Companies Act 1985.

2) TAXATION

The accrued tax charge for the six month period is based on an estimated effective tax rate of nil, after allowance for utilisation of tax losses brought forward in subsidiaries and prior year adjustments, (period to 31 July 2007: effective tax rate nil, period to 31 January 2008: effective tax rate 8.6 per cent.).

3) LOSS PER SHARE

Basic loss per share is based on the net loss for the period of £102,000 attributable to equity holders of the parent divided by the weighted average number of ordinary shares in issue during the period of 600,000,000, (period to 31 July 2007: loss £3,000 divided by the weighted average number of 353,658,537 shares; period to 31 January 2008: loss £63,000 divided by the weighted average of 456,050,955 shares). Fully diluted earnings per share are the same as basic earnings per share.

4) SHARE CAPITAL
Number
£’000
Authorised ordinary shares of 1p:
 
 
 
 
 
At 31 July 2007, 31 January 2008 and 31 July 2008
1,000,000,000
1,000
 
 
 
Allotted, issued and fully paid ordinary shares of 1p:
 
 
 
 
 
At 31 July 2007, 31 January 2008 and 31 July 2008
600,000,000
600
 
 

5) RELATED PARTY TRANSACTIONS

During the period the Company entered into the following transactions with Ora Capital Partners Plc (ORA) which as at 31 July 2008 held 45.25% of the Company's issued share capital.

 
Six months to
31 July
 2008
Period to
31 July
2007
Period to
31 January 2008
 
(Unaudited)
(Unaudited)
(Audited)
 
£000
£000
£000
Management consultancy fees charged by ORA
6
7
18
 

 

During the period the Company's wholly owned subsidiary, Oxray Ltd, borrowed £nil (31 July 2007: £100,000)  from the Company for working capital purposes. The loan is non-interest bearing, is repayable on demand and the outstanding balance at 31 July 2008 was £200,000 (31 July 2007: £100,000).

6) INTERIM FINANCIAL REPORT

A copy of this interim report will be distributed to shareholders and is also available on the Company's website at www.oxecoplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR ILFLDISLELIT
Date   Source Headline
18th Oct 20177:00 amRNSDirectorate Change
11th Oct 20177:15 amRNSHardman Research: Dual revenue stream growth
28th Sep 20173:15 pmRNSUnaudited Interim Results
8th Sep 20177:00 amRNSNotice of Results
5th Sep 20173:52 pmRNSNotification Of Major Holdings
30th Aug 20175:15 pmRNSIssue of Equity
16th Aug 201712:22 pmRNSHolding(s) in Company
11th Aug 20173:45 pmRNSHolding(s) in Company
11th Aug 20173:37 pmRNSHolding(s) in Company
10th Aug 20174:30 pmRNSHolding(s) in Company
10th Aug 20172:45 pmRNSHolding(s) in Company
10th Aug 20171:10 pmRNSHardman Research: CellRight transforming US growth
10th Aug 201710:10 amRNSHolding(s) in Company
9th Aug 20173:00 pmRNSHolding(s) in Company
9th Aug 20172:30 pmRNSDirector/PDMR Shareholding
8th Aug 20171:41 pmRNSResults of General Meeting and Total Voting Rights
21st Jul 20176:00 pmRNSCirc re.CellRight Acquisition
21st Jul 20178:05 amRNSSuccessful fundraising of £40 million
20th Jul 20176:03 pmRNSProposed Acquisition and Placing
30th Jun 201712:00 pmRNSResult of AGM
2nd Jun 20177:00 amRNSAnnual results for period ended 31 December 2016
31st May 201710:46 amRNSPotential Acquisition Update
19th May 201711:35 amRNSPotential Acquisition
3rd Apr 20177:00 amRNSIssue of Equity
13th Mar 20177:10 amRNSHardman Research: Addressing woundcare in the US
1st Mar 20177:00 amRNSInnovative Technology Contract Awarded
2nd Feb 20177:00 amRNSDermaPure® added to the Federal Supply Schedule
6th Jan 20177:00 amRNSDirectorate Change
9th Dec 20167:15 amRNSHardman Research: a/c change: Not simply 11/12ths
7th Dec 20161:04 pmRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Dec 20167:00 amRNSDermaPure secures GPO agreement with Premier, Inc.
28th Nov 20167:05 amRNSOrthoPureT XT update
22nd Nov 20167:00 amRNSDirectorate Change
12th Oct 20167:00 amRNSInterim Results
28th Sep 20167:00 amRNSNotice of Interim Results
15th Sep 20163:07 pmRNSEdison issues outlook on Tissue Regenix
1st Sep 20167:00 amRNSDermaPure® Medicare coverage in further 10 States
3rd Aug 20167:15 amRNSHardman & Co Research Report on: Tissue Regenix
28th Jul 201610:58 amRNSEdison research outlook on Tissue Regenix (TRX)
18th Jul 201611:20 amRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
11th Jul 20167:00 amRNSOrthopaedics Update
4th Jul 201610:41 amRNSResult of AGM
1st Jul 20167:00 amRNSDermaPure® secures first GPO contract in US
30th Jun 20167:00 amRNSDeferred Annual Bonus Scheme
1st Jun 20167:00 amRNSNew appointment adds clinical expertise to Board
23rd May 20167:00 amRNSPreliminary results for year ended 31 January 2016
20th Apr 20167:00 amRNSNotice of Preliminary Results
14th Apr 20167:00 amRNSChange of Registered Office
24th Mar 20164:40 pmRNSSecond Price Monitoring Extn
24th Mar 20164:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.